receptor tyrosine kinase inhibitors (Jiangsu Simcere pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug Namereceptor tyrosine kinase inhibitors (Jiangsu Simcere pharmaceuticals)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionStem cell growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 antagonistsPlatelet-derived growth factor receptor beta inhibitors

TargetsStem cell growth factor receptorVascular endothelial growth factor receptor 2Platelet-derived growth factor receptor beta

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesSimcere Pharmaceutical Group Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSimcere Pharmaceutical Group Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A